Anti-inflammatory effects of BT-201, an n-butanol extract of Panax notoginseng, observed in vitro and in a collagen-induced arthritis model

Clinical Nutrition

Volumn 26, Issue 6, 2007, Pages 785-791

  Chang, Sun Hwa ^a   Choi, Youngnim ^b   Park, Jung Ae ^a   Jung, Dong Sik ^a   Shin, Jieun ^b   Yang, Ji Hyun ^b   Ko, Seon Yle ^a,c   Kim, Se Won ^a   Kim, Jung Keun ^a  

^a Oscotec Inc   (South Korea)

^b School of Dentistry   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Arthritis; MAPK; NF B; Panax notoginseng; TNF

Indexed keywords

ANTIBODY; BT 201; BUTANOL; COLLAGEN TYPE 2; COLLAGENASE 3; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GINSENOSIDE RB 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTOGINSENOSIDE R1; PANAX NOTOGINSENG EXTRACT; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY DISEASE; MALE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED DBA; NITRIC OXIDE; PANAX NOTOGINSENG; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36148941379     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2007.07.008     Document Type: Article

References (35)

1. O'Dell J.R. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350 (2004) 2591-2602
2. Feldmann M., Brennan F.M., and Naini R.N. Rhematoid arthritis. Cell 85 (1996) 307-310
3. Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42 Suppl. 2 (2003) ii11-ii16
4. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
5. Smolen J.S., and Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2 (2003) 473-488
6. Butler D.M., Maini R.N., Feldmann M., and Brennan F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6 (1995) 225-230
7. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 12 (2003) 1087-1095
8. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 350 (2004) 2167-2179
9. Lipsky P.E., van der Heijde D.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 (2000) 1594-1602
10. Chang S.H., Sung H.C., Choi Y., Ko S.Y., Lee B.E., Baek D.H., et al. Suppressive effect of AIF, a water extract from three herbs, on collagen-induced arthritis in mice. Int Immunopharmacol 5 (2005) 1365-1372
11. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., and Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 283 (1980) 666-668
12. Choi Y., Simon-Stoos K., and Puck J.M. Hypo-active variant of IL-2 and associated decreased T cell activation contribute to impaired apoptosis in autoimmune prone MRL mice. Eur J Immunol 32 (2002) 677-685
13. Otero M., Lago R., Gomez R., Dieguez C., Lago F., Gomez-Reino J., et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 45 (2006) 944-950
14. Juarranz Y., Abad C., Martinez C., Arranz A., Gutierrez-Canas I., Rosignoli F., et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7 (2005) R1034-R1045
15. Mitchell P.G., Magna H.A., Reeves L.M., Lopresti-Morrow L.L., Yocum S.A., Rosner P.J., et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97 (1996) 761-768
16. Fitzgerald K.A., Rowe D.C., and Golenbock D.T. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 6 (2004) 1361-1367
17. Hsu T.C., Young M.R., Cmarik J., and Colburn N.H. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28 (2000) 1338-1348
18. Schett G., Tohidast-Akrad M., Smolen J.S., Schmid B.J., Steiner C.W., Bitzan P., et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43 (2000) 2501-2512
19. Aupperle K., Bennett B., Han Z., Boyle D., Manning A., and Firestein G. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 166 (2001) 2705-2711
20. Tak P.P., Gerlag D.M., Aupperle K.R., van de Geest D.A., Overbeek M., Bennett B.L., et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44 (2001) 1897-1907
21. Gao B., Calhoun K., and Fang D. The proinflammatory cytokines IL-1beta and TNF-alpha induce the expression of synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway. Arthritis Res Ther 8 (2006) R172
22. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108 (2001) 73-81
23. Campbell J., Ciesielski C.J., Hunt A.E., Horwood N.J., Beech J.T., Hayes L.A., et al. A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol 173 (2004) 6928-6937
24. Scizhen L. Bone Cho Kang Mook [Compendium of material medica] 1978 [1590 A.D.].
25. Li S.H., and Chu Y. Anti-inflammatory effects of total saponins of Panax notoginseng. Zhongguo Yao Li Xue Bao 20 (1999) 551-554
26. Park W.H., Lee S.K., and Kim C.H. A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. Life Sci 76 (2005) 1675-1690
27. Rhule A., Navarro S., Smith J.R., and Shepherd D.M. Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells. J Ethnopharmacol 106 (2006) 121-128
28. Wang Y, Peng D, Huang W, Zhou X, Liu J, Fang Y. Mechanism of altered TNF-alpha expression by macrophage and the modulatory effect of Panax notoginseng saponins in scald mice. Burns 2006;27 [Epub ahead of print].
29. Zhou L.G., Zheng G.Z., Gan F.Y., Wang S.L., Yang C.R., and Xu C. Separation and identification of main medicinal saponin components from mass cell cultures of Panax notoginseng (Burk) F. H. Chen. Yao Xue Xue Bao 26 (1991) 876-880
30. Zhang H.S., and Wang S.Q. Notoginsenoside R1 inhibits TNF-alpha-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. Free Radic Biol Med 40 (2006) 1664-1674
31. Zhang H.S., and Wang S.Q. Notoginsenoside R1 from Panax notoginseng inhibits TNF-alpha-induced PAI-1 production in human aortic smooth muscle cells. Vascul Pharmacol 44 (2006) 224-230
32. Han M., Sha X., Wu Y., and Fang X. Oral absorption of ginsenoside Rb1 using in vitro and in vivo models. Planta Med 72 (2006) 398-404
33. Han M., and Fang X.L. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin 27 (2006) 499-505
34. Liang F., and Hua J.X. Absorption profiles of sanchinoside R1 and ginsenoside Rg1 in the rat intestine. Eur J Drug Metab Pharmacokinet 30 (2005) 261-268
35. Xu Q.F., Fang X.L., and Chen D.F. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84 (2003) 187-192